Patients with tumors positive for IGF1R mRNA expression had a shorter progression-free and overall survival when compared to the negative sub-group ( 6.1 vs. 7.4 months , p = 0.039 and 10.9 vs. 14.3 months , p = 0.038 , respectively ) .